Logo

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Share this

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shots:

  • The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab- 1mg/kg) + Yervoy (ipilimumab- 3mg/kg) in patients with mCRPC
  • P-II study result in asymptomatic or minimally symptomatic patients & patients who progressed after taxane-based CT ORR @ 11.9/13.5 mos. (25%- 10%); GRADE 3AEs or 5AEs (42%- 53%)- Presented at ASCO 2019
  • Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US- EU- Japan & China

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions